TY - JOUR
T1 - Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma
T2 - Samarium-153- EDTMP and Radium-223
AU - Anderson, Peter M.
AU - Subbiah, Vivek
AU - Rohren, Eric
N1 - Funding Information:
Peter M. Anderson acknowledges Greg Wiseman and Oyvind Bruland for their advice and sharing ideas during in the development of bone-seeking radiopharmaceuticals for osteosarcoma and Norman Jaffe for his mentorship when working with metastatic osteosarcoma patients. Research has been supported by the Shannon Wilkes Osteosarcoma fund, and Lauren Edwards Behr sarcoma research fund, Sarah’s Garden of Hope. The University of Texas MD Anderson Cancer Center is supported by Cancer Center Support Grant No. CA 016672. Dr. Anderson was supported by the Curtis Distinguished Professorship and is currently partially supported by Levine Cancer Institute.
Publisher Copyright:
© Springer International Publishing Switzerland 2014.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2014
Y1 - 2014
N2 - Osteosarcoma is a cancer characterized by formation of bone by malignant cells. Routine bone scan imaging with Tc-99m-MDP is done at diagnosis to evaluate primary tumor uptake and check for bone metastases. At time of relapse the Tc-99m-MDP bone scan also provides a specifi c means to assess formation of bone by malignant osteosarcoma cells and the potential for bone-seeking radiopharma-ceuticals to deliver radioactivity directly into osteoblastic osteosarcoma lesions. This chapter will review and compare a bone-seeking radiopharmaceutical that emits beta-particles, samarium-153-EDTMP, with an alpha-particle emitter, radium-223. The charged alpha particles from radium-223 have far more mass and energy than beta particles (electrons) from Sm-153-EDTMP. Because radium-223 has less marrow toxicity and more radiobiological effectiveness, especially if inside the bone forming cancer cell than samarium-153-EDTMP, radium-223 may have greater potential to become widely used against osteosarcoma as a targeted therapy. Radium-223 also has more potential to be used with chemotherapy against osteosar-coma and bone metastases. Because osteosarcoma makes bone and radium-223 acts like calcium, this radiopharmaceutical could possibly become a new targeted means to achieve safe and effective reduction of tumor burden as well as facilitate better surgery and/or radiotherapy for diffi cult to resect large, or metastatic tumors.
AB - Osteosarcoma is a cancer characterized by formation of bone by malignant cells. Routine bone scan imaging with Tc-99m-MDP is done at diagnosis to evaluate primary tumor uptake and check for bone metastases. At time of relapse the Tc-99m-MDP bone scan also provides a specifi c means to assess formation of bone by malignant osteosarcoma cells and the potential for bone-seeking radiopharma-ceuticals to deliver radioactivity directly into osteoblastic osteosarcoma lesions. This chapter will review and compare a bone-seeking radiopharmaceutical that emits beta-particles, samarium-153-EDTMP, with an alpha-particle emitter, radium-223. The charged alpha particles from radium-223 have far more mass and energy than beta particles (electrons) from Sm-153-EDTMP. Because radium-223 has less marrow toxicity and more radiobiological effectiveness, especially if inside the bone forming cancer cell than samarium-153-EDTMP, radium-223 may have greater potential to become widely used against osteosarcoma as a targeted therapy. Radium-223 also has more potential to be used with chemotherapy against osteosar-coma and bone metastases. Because osteosarcoma makes bone and radium-223 acts like calcium, this radiopharmaceutical could possibly become a new targeted means to achieve safe and effective reduction of tumor burden as well as facilitate better surgery and/or radiotherapy for diffi cult to resect large, or metastatic tumors.
KW - Beta particle
KW - Bone scan for screening
KW - Double strand DNA breaks
KW - Internal radiotherapy
KW - Osteosarcoma
KW - Radiobiological effectiveness (RBE)
KW - Radium-223
KW - Resistance is futile
KW - Samarium-153
KW - Alpha particle
UR - http://www.scopus.com/inward/record.url?scp=84907164048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907164048&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-04843-7_16
DO - 10.1007/978-3-319-04843-7_16
M3 - Article
C2 - 24924181
AN - SCOPUS:84907164048
VL - 804
SP - 291
EP - 304
JO - Advances in experimental medicine and biology
JF - Advances in experimental medicine and biology
SN - 0065-2598
ER -